Literature DB >> 11406549

Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule.

A Trojan1, M Witzens, J L Schultze, R H Vonderheide, S Harig, A M Krackhardt, R A Stahel, J G Gribben.   

Abstract

A growing number of human tumor antigens have been described that can be recognized by CTLs in a MHC class I restricted fashion. The epithelial cell adhesion molecule (Ep-CAM) is expressed in a variety of human tumors and has attracted attention as a therapeutic target for monoclonal antibody serotherapy. We have identified immunogenic peptides derived from Ep-CAM, that bind to human leukocyte antigen-A*0201 and elicit strong peptide-specific human CTL responses, demonstrating that there is an effective T-cell repertoire against these Ep-CAM-derived peptides that can be recruited. Alterations to these peptides were made to increase their binding affinity to MHC class I molecules. The use of such "heteroclitic" peptides allowed generation of cytotoxic T cells that demonstrated increased killing of target cells pulsed not only with the heteroclitic but also with the native peptide. Most important, CTL cell lines that are generated against these peptides specifically lyse epithelial tumor cells expressing Ep-CAM but not normal hematopoietic or bronchial epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11406549

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Sequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses.

Authors:  Rekha Singh; Alan L Rothman; James Potts; Farshad Guirakhoo; Francis A Ennis; Sharone Green
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  Antitumor cytotoxic T-cell response induced by a survivin peptide mimic.

Authors:  Michael J Ciesielski; Manmeet S Ahluwalia; Stephan A Munich; Molly Orton; Tara Barone; Asher Chanan-Khan; Robert A Fenstermaker
Journal:  Cancer Immunol Immunother       Date:  2010-04-27       Impact factor: 6.968

3.  Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide.

Authors:  Katja Mauerer Zirlik; David Zahrieh; Donna Neuberg; John G Gribben
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

Review 4.  Novel vaccines for glioblastoma: clinical update and perspective.

Authors:  Evan K Winograd; Michael J Ciesielski; Robert A Fenstermaker
Journal:  Immunotherapy       Date:  2016-11       Impact factor: 4.196

5.  Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens.

Authors:  Kimberly R Jordan; Rachel H McMahan; Charles B Kemmler; John W Kappler; Jill E Slansky
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-26       Impact factor: 11.205

6.  Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma.

Authors:  Xiao Li; Zhuochao Zhang; Guoying Lin; Yuanxing Gao; Zhen Yan; Heliang Yin; Bingyi Sun; Fangyuan Wang; Haijun Zhang; Hong Chen; Dayong Cao
Journal:  Tumour Biol       Date:  2016-03-07

7.  Glioma big potassium channel expression in human cancers and possible T cell epitopes for their immunotherapy.

Authors:  Lisheng Ge; Neil T Hoa; Andrew N Cornforth; Daniela A Bota; Anthony Mai; Dong In Kim; Shiun-Kwei Chiou; Michelle J Hickey; Carol A Kruse; Martin R Jadus
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

8.  Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas.

Authors:  G N Berta; B Mognetti; M Spadaro; E Trione; A Amici; G Forni; F Di Carlo; F Cavallo
Journal:  Br J Cancer       Date:  2005-11-28       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.